Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
A COVID-19 vaccine candidate being developed by Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, has yielded positive animal data and is on track to clinical trials, which are expected to start this summer and end by November next year.…
To read the full story
Related Article
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- Medicago Successfully Produces COVID-19 Vaccine Candidate
March 13, 2020
BUSINESS
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
- Fuji, Richter Expand Gynecology Partnership to Accelerate R&D
February 4, 2026
- Senju, Novartis Ink Promotion Tie-Up for Eye Drug Beovu in Japan
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…